OUR PRIORITY IS YOU | Click here for Visitation Guidelines & more

CALL US: 1-304-598-1200

Cancer Clinical Trials

Clinical trials are research studies for cancer treatments that are still in the development phase.

The Mon Health Cancer Center is committed to participation in clinical trials for our patients on a case-by-case basis. As an affiliate member of NRG Oncology, we have the ability to offer clinical trials associated with the leading oncology research centers and national cooperative groups.

It’s important to note that, for many reasons, not all patients will be eligible for a clinical trial. There are very strict patient eligibility requirements that are specific to each clinical trial.  We look forward to the opportunity to discuss this possible option with you.

Clinical trials are done in phases. Each phase has a different purpose, the National Institute of Health says:

  • Phase I trials use a small group of people, usually 20-80, to check the safety, dosage and side effects of a treatment.
  • Phase II trials expand to 100-300 people and look at the effectiveness and safety of a treatment.
  • Phase III trials include 1,000-3,000 people and try to confirm the results of the earlier trials and compare the new treatment with other commonly used treatments.

Mon Health Medical Center primarily focuses on Phase II and Phase III trials. If interested, please speak to your doctor or call our Clinical Trial Coordinator at 304-598-6581.

Open Clinical Trials for Hematology Oncology

S1207:  Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of Everolimus in patients with high-risk hormone receptor-positive AND HER2/neu negative breast cancer.   

ECOG-EAY131: Match Study - A Phase II precision medicine trial that seeks to determine whether matching certain drugs or drug combinations in adults whose tumors have specific gene abnormalities will effectively treat their cancer, regardless of their cancer type.

Open Clinical Trials for Gynecologic Oncology

ProMark:  A Collaborative Study with The University of Pittsburgh Medical Centers. Prognostic Marker: Acquisition of Blood Samples and Tissue for Research Purposes. 

NRG-GY005: A Randomized Phase II/III study of the combination of Cebiranib and Olaparib compared to Cediranib or Olaparib alone, of standard of care chemotherapy in women with recurrent platinum-resistant or refractory ovarian, fallopian tube or primary peritoneal cancer (COCOS).

ICON-eXACT sCIENCES 2018-01: Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors

NRG-GY009 - TEMPORARILY CLOSED TO ACCURAL: A randomized, Phase II/III study of pegylated liposomal doxorubicin and CTEP-supplied Atezolizumab (IND #134427) versus pegylated liposomal doxorubicin/bevacizumad and CTEP-supplied atezolizumab versus pegylated liposomal doxorubicin/bevacizumab in platinum resistant ovarian cancer.

NRG-GY018 - WILL BE OPENING IN THE NEXT FEW WEEK: A Phase III randomized, placebo-controlled study of pembrolizumab (MK-3475, NSC #776864) in addition to paclitaxel and carboplatin for measurable stage III or IVA, stage IVB or recurrent endometrial cancer.

If you would like to learn more about clinical trials, here are some useful links:

ClinicalTrials.gov—a worldwide clinical studies database from the US National Institutes of Health 
Cancer.gov—a cancer-specific resource on clinical trials from the National Cancer Institute at the National Institutes of Health
NRG Oncology – a resource for the clinical trials by the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG) and the Gynecologic Oncology Group (GOG)  
Back to Top
Contact the Mon Health Cancer Center
1200 JD Anderson Drive
Morgantown, WV 26505

Patient Information:
General Information:
Medical Oncology:
Gynecologic Oncology:
Infusion Center: 
Radiation Oncology
Wig Bank

Send us a message